In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Enoxacin is a new quinolone carboxylic acid compound. Its activity against 740 bacterial isolates was determined. It inhibited 90% Escherichia coli, Klebsiella sp., Aeromonas sp., Enterobacter spp., Serratia spp., Proteus mirabilis, and Morganella morganii at less than or equal to 0.8 micrograms/ml. The majority of Pseudomonas aeruginosa was inhibited by less than or equal to 3.1 micrograms/ml. Haemophilus spp. and Neisseria spp. were inhibited by less than 0.1 micrograms/ml. Although most Staphylococcus aureus were inhibited by 3.1 micrograms/ml, some streptococcal species had minimal inhibitory concentrations of 6.3 to 12.5 micrograms/ml and Bacteroides sp. had minimal inhibitory concentrations greater than or equal to 25 micrograms/ml. Activity of enoxacin and norfloxacin was similar. Enoxacin inhibited organisms resistant to cefotaxime, moxalactam, gentamicin, and piperacillin. Enoxacin was less active in urine at an acid pH than in broth, but serum did not decrease minimal inhibitory concentrations or minimal bactericidal concentrations. There was no major difference between minimal inhibitory concentrations and minimal bactericidal concentrations. Resistance frequency development was less than 10(-9) for most bacterial species.